Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry

scientific article

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2016PLoSO..1168376P
P356DOI10.1371/JOURNAL.PONE.0168376
P932PMC publication ID5172579
P698PubMed publication ID27997580

P50authorCristina ScarpazzaQ62058593
Luca ProsperiniQ64878102
P2093author name stringRuggero Capra
Mirco Cosottini
Simonetta Gerevini
Lucia Moiola
Italian PML study group
Nicola de Rossi
P2860cites workRating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)Q22241644
Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoringQ22242013
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainQ24619923
Progressive multifocal leukoencephalopathy: current treatment options and future perspectivesQ26776236
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological SocietyQ59389216
Kurtzke scales revisited: the application of psychometric methods to clinical intuitionQ73699544
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyQ84114256
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupQ26780412
Neurological immune reconstitution inflammatory response: riding the tide of immune recoveryQ28082309
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringQ28243804
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple SclerosisQ30278095
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.Q30583907
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease SectionQ30613846
Inflammatory Reaction in Progressive Multifocal Leukoencephalopathy: Harmful or Beneficial?Q30787765
The Evolving Face of Human Immunodeficiency Virus-Related Progressive Multifocal Leukoencephalopathy: Defining a Consensus TerminologyQ30787783
Progressive multifocal leukoencephalopathy in HIV-1 infectionQ33506561
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisQ33893285
Persistence and pathogenesis of the neurotropic polyomavirus JCQ34459843
Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumabQ34556743
Outcome and survival of asymptomatic PML in natalizumab-treated MS patientsQ34562841
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Q34803324
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.Q35215625
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MSQ35938575
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathyQ36234255
Diagnostic delay in progressive multifocal leukoencephalopathyQ36891735
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesQ37714089
Progressive multifocal leukoencephalopathy in patients with multiple sclerosisQ38089536
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathyQ39418067
Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 CasesQ40922077
Natalizumab-related PML 2 weeks after negative anti-JCV antibody assayQ40994617
MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.Q41361912
MRI pattern in asymptomatic natalizumab-associated PML.Q41745436
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosisQ42268433
Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?Q43897444
Variations in functioning and disability in multiple sclerosis. A two-year prospective studyQ45138514
Anti-JC virus antibodies: implications for PML risk stratificationQ45373492
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.Q46007698
Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosisQ47202056
Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumabQ48119795
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patientsQ48386105
The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?Q48401612
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectItalyQ38
progressive multifocal leukoencephalopathyQ704930
multiple sclerosisQ8277
P304page(s)e0168376
P577publication date2016-01-01
P1433published inPLOS OneQ564954
P1476titleNatalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
P478volume11

Reverse relations

cites work (P2860)
Q40100891Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Q39409318Immunosenescence: the Role of Aging in the Predisposition to Neuro-Infectious Complications Arising from the Treatment of Multiple Sclerosis
Q41455235Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
Q39391443Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
Q42363059Multidisciplinary Rehabilitation is Efficacious and Induces Neural Plasticity in Multiple Sclerosis even when Complicated by Progressive Multifocal Leukoencephalopathy
Q91830971Progressive Multifocal Leukoencephalopathy: Current Insights
Q45325710The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Q58864832The still under-investigated role of cognitive deficits in PML diagnosis
Q47812653To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.
Q90288758Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration
Q64274762Treatment of natalizumab-associated PML with filgrastim

Search more.